PBA
THRX

Paradigm Biocapital Advisors’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Paradigm Biocapital Advisors’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,950,327
Closed -$18.2M – 38
2023
Q2 		$18.2M Buy
1,950,327
+445,000
+30% +$4.39M 1.41% 29
2023
Q1 		$13.4M Buy
+1,505,327
New +$14.8M 1.27% 23

Other funds holding THRX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Paradigm Biocapital Advisors's THRX Position: Q3 2023 in Review

Paradigm Biocapital Advisors sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q3 2023, closing a stake of 1,950,327 shares — an estimated $18.2M sold.

Paradigm Biocapital Advisors first reported a position in THRX in Q1 2023 and held it in 2 quarters. The position peaked at $18.2M in Q2 2023. 63 funds tracked by Wall St. Rank hold THRX as of Q3 2023.

  • Paradigm Biocapital Advisors reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 1,950,327 Theseus Pharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $18.2M.
  • Paradigm Biocapital Advisors first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q1 2023 and held it in 2 quarters.
  • Paradigm Biocapital Advisors's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $18.2M in Q2 2023.
  • 63 funds tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on Paradigm Biocapital Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.